With the emergence of new data on IL28B, it is expected to be involved in upcoming trials to update these algorithms.In conclusion, besides viral factors, several host factors are responsible for the responsiveness to HCV therapy with Peg-IFN-α/RBV, including host genetic factors, age, ethnicity, gender, menopause, cirrhosis, BMI, steatosis, IR, and T2DM. Here, IFNA1 is linked to Cirrhosis.